For the quarter ended September 2025, Edwards Lifesciences (EW) reported revenue of $1.55 billion, up 14.7% over the same period last year. EPS came in at $0.67, compared to $0.67 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $1.5 billion, representing a surprise of +3.26%. The company delivered an EPS surprise of +13.56%, with the consensus EPS estimate being $0.59.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Edwards Lifesciences performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Europe: $387.9 million compared to the $350.29 million average estimate based on two analysts. The reported number represents a change of +21.3% year over year.
- Net Sales- Outside of the United States: $645.6 million versus the two-analyst average estimate of $636.85 million. The reported number represents a year-over-year change of +17.4%.
- Net Sales- United States: $907.5 million compared to the $862.73 million average estimate based on two analysts. The reported number represents a change of +12.8% year over year.
- Net Sales- Japan: $90.1 million versus the two-analyst average estimate of $87.3 million. The reported number represents a year-over-year change of +10.7%.
- Net Sales- Rest of World: $167.6 million versus the two-analyst average estimate of $199.26 million. The reported number represents a year-over-year change of +12.8%.
- Net Sales by Product Group- Transcatheter Mitral and Tricuspid Therapies: $145.2 million versus the eight-analyst average estimate of $141.97 million. The reported number represents a year-over-year change of +59.4%.
- Net Sales by Product Group- Surgical Structural Heart: $258 million versus the eight-analyst average estimate of $255.09 million. The reported number represents a year-over-year change of +7.5%.
- Net Sales by Product Group- Transcatheter Aortic Valve Replacement: $1.15 billion compared to the $1.11 billion average estimate based on eight analysts. The reported number represents a change of +12.4% year over year.
View all Key Company Metrics for Edwards Lifesciences here>>>
Shares of Edwards Lifesciences have returned +8.4% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Edwards Lifesciences Corporation (EW): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
